Patrick Mahaffy, CEO & Founder, Clovis Oncology
Dan Burgess, CEO & Founder, Rempex Pharmaceuticals
Faheem Hasnain, President & CEO, Receptos
Remi Brouard, Vice President External Innovation, Sanofi-Aventis R&D
Polly Murphy, Vice President, Worldwide Business Development, Pfizer
Mark Noguchi, Gloabl Head of Alliance Management, Roche
Roger Pomerantz, SVP and Head Worldwide Licensing, Merck
Mark Edwards, Managing Director, Bioscience Advisors
George Golumbeski, Senior Vice President Business Development, Celgene Corporation
Kurt Graves, Executive Chairman, Intarcia Therapeutics, Inc.
Natasha Hernday, VP of Corporate Development, Seattle Genetics
Paul Laikind, Chief Business Officer and Senior VP of Business Development, Sanford Burnham Research Institute
Jeremy Levin, Senior Vice President, Strategy, Alliances and Transactions, Bristol-Meyers Squibb
Brian McVeigh, Vice President, WWBD Transactions Investment Management, GlaxoSmithKline Pharmaceuticals
Bob More, General Partner, Frazier Healthcare
Anna Protopapas, SVP Corporate Development and Strategy, Millennium Pharmaceuticals
Melinda Richter, Prescience International
Tony Rosenberg, Head of Global BD & Licensing, Novartis
Jim Schaeffer, Executive Director Worldwide Licensing & External Research, Merck Research Laboratories
Laura Shawver, CEO, Cleave Biosciences
Keith Donnermeyer, Partner, Deloitte & Touche LLP
Luke Evnin, Managing Director, MPM Capital
Andy Schwab, Founder and Managing Partner, 5AM Ventures
Phillipe Tinmouth, Vice President, Business Development & Alliance Management, Vertex Pharmaceuticals, Inc.
Kurt von Emster, Managing Director, venBio LLC
Karen Bernstein, Chairman & Editor-in-Chief, BioCentury
Ben Bonifant, Practice Area Leader, Campbell Alliance